Q-omics provides the consensus-scored RPUSD2 profile across patient tissues and cancer cell-line models. RPUSD2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, RPUSD2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RPUSD2 protein abundance shows 20,465 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SCLC, COAD, and LSCC as cancer lineages where RPUSD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPUSD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPUSD2 survival associations across molecular data types. RPUSD2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPUSD2 RNA expression–survival associations across cancer types. High RPUSD2 expression shows unfavorable associations in COAD, but favorable associations in SCLC, KIRC, LUSC, UVM and GBM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for RPUSD2 RNA expression.
This table summarizes RPUSD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RPUSD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPUSD2 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, STAD, LIHC and BLCA. The COAD box plot shows higher RPUSD2 RNA expression in tumor versus normal tissue (log2 FC = +0.994, t-test p < 0.001).
This table shows molecular features associated with RPUSD2 in patient tissues and cancer cell lines. In patient samples, RPUSD2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPUSD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
